Presentations Lexeo Corporate Presentation – June 2026 2.2 MB Regulatory Update of LX2006 for the Treatment of Friedrich Ataxia Cardiomyopathy - June 2026 1.3 MB Interim Clinical Data from the Phase 1/2 HEROIC-PKP2 Trial of LX2020 for Arrhythmogenic Cardiomyopathy Caused by Mutations in the PKP2 Gene Presentation 1.6 MB Regulatory Update and Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy – October 2025 1.3 MB Interim Phase 1/2 Clinical Data of LX1001 for the Treatment of APOE4-Associated Alzheimer’s Disease – October 2024 1.3 MB Upcoming Events More events are coming soon. Past Events Year All202620252024 Jun 15, 2026 at 8:00 AM EDT Regulatory Update of LX2006 for the Treatment of Friedrich Ataxia Cardiomyopathy Listen to webcast Regulatory Update of LX2006 for the Treatment of Friedrich Ataxia Cardiomyopathy - June 2026 1.3 MB May 19, 2026 at 2:35 PM EDT 2026 RBC Capital Markets Global Healthcare Conference Listen to webcast Mar 10, 2026 at 10:00 AM EDT Leerink Global Healthcare Conference Listen to webcast Feb 26, 2026 at 10:40 AM EST Oppenheimer 36th Annual Healthcare Life Sciences Conference Listen to Webcast Feb 12, 2026 at 12:30 PM EST Guggenheim Emerging Outlook: Biotech Summit 2026 Listen to Webcast Jan 14, 2026 at 7:30 AM PST 44th Annual J.P. Morgan Healthcare Conference Listen to Webcast Jan 12, 2026 at 8:00 AM EST Interim Clinical Data from the Phase 1/2 HEROIC-PKP2 Trial of LX2020 for Arrhythmogenic Cardiomyopathy Caused by Mutations in the PKP2 Gene Listen to webcast Interim Clinical Data from the Phase 1/2 HEROIC-PKP2 Trial of LX2020 for Arrhythmogenic Cardiomyopathy Caused by Mutations in the PKP2 Gene Presentation 1.6 MB
Interim Clinical Data from the Phase 1/2 HEROIC-PKP2 Trial of LX2020 for Arrhythmogenic Cardiomyopathy Caused by Mutations in the PKP2 Gene Presentation 1.6 MB
Interim Clinical Data from the Phase 1/2 HEROIC-PKP2 Trial of LX2020 for Arrhythmogenic Cardiomyopathy Caused by Mutations in the PKP2 Gene Presentation 1.6 MB
Regulatory Update and Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy – October 2025 1.3 MB
Regulatory Update and Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy – October 2025 1.3 MB
Interim Phase 1/2 Clinical Data of LX1001 for the Treatment of APOE4-Associated Alzheimer’s Disease – October 2024 1.3 MB
Interim Phase 1/2 Clinical Data of LX1001 for the Treatment of APOE4-Associated Alzheimer’s Disease – October 2024 1.3 MB
Interim Clinical Data from the Phase 1/2 HEROIC-PKP2 Trial of LX2020 for Arrhythmogenic Cardiomyopathy Caused by Mutations in the PKP2 Gene Presentation 1.6 MB